FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
Decision brief
Answer first · skim in under a minute
The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for generic eribulin mesylate injection. This approval offers a new therapeutic option for patients with pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.
On June 3, 2026, the FDA approved Natco Pharma’s ANDA for generic Eribulin Mesylate Injection with Lupin, creating a multi-source alternative to Eisai’s Halaven for pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.
Contents9 sections
Key Takeaways
- FDA cleared Natco’s ANDA for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, on June 3, 2026.
- The generic is bioequivalent to Eisai’s Halaven and carries the same two oncology indications.
- IQVIA MAT April 2026 put U.S. Halaven sales at about USD 43.7 million before generic entry.
- Brand erosion timing will hinge on launch sequencing, contracting, and how many additional ANDAs follow.
What did the FDA approve for Eribulin Mesylate?
Lupin and Natco announced U.S. FDA approval of Natco’s Abbreviated New Drug Application for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials.
According to the June 3, 2026 PR Newswire release, the product is bioequivalent to the reference listed drug Halaven Injection from Eisai.
An ANDA path means the agency accepted therapeutic equivalence without requiring the sponsors to rerun full clinical efficacy programs for the molecule.
Which labeled indications does generic Eribulin Mesylate carry?
The approved generic mirrors Halaven’s labeled uses for adults:
- Metastatic breast cancer after at least two prior chemotherapeutic regimens for metastatic disease
- Unresectable or metastatic liposarcoma after a prior anthracycline-containing regimen
NCI’s drug monograph for eribulin mesylate summarizes the same metastatic breast cancer and liposarcoma use cases for the branded product that the generic references.
How big is the Halaven franchise under pressure?
Lupin and Natco reported that Eribulin Mesylate Injection (RLD Halaven) had estimated annual U.S. sales of USD 43.7 million based on IQVIA MAT April 2026.
That figure is a company-cited market size, not a forecast of generic capture. Multi-source injectables often erode originator share over several quarters as hospital and specialty pharmacy contracts reset.
DailyMed listing pages for eribulin mesylate labeling remain the public label repository clinicians and payers use to confirm strength, route, and warning language as generics ship.
Brand loyalty, contracted access, and infusion-center familiarity can slow switch velocity even after an ANDA clears. In analogous oncology injectable launches, originators often keep a residual share while payers push preferred generic status at the plan level.
Why does ANDA entry matter for BD and investors?
For business-development teams, a complex injectable ANDA adds an oncology SKU that can sit beside existing hospital portfolios without a new Phase 3 outlay.
Eribulin is a microtubule dynamics inhibitor derived from a marine natural product scaffold. That chemistry and the sterile injectable presentation raise the manufacturing bar relative to simple oral solid generics, which is why ANDA holders with sterile fill-finish capacity treat this as a limited-competition opportunity rather than a commodity tablet race.
For Eisai watchers, the catalyst is franchise erosion risk on Halaven rather than a novel mechanism. Share loss usually tracks launch timing, wholesaler fill, and whether additional ANDA holders enter the same 0.5 mg/mL strength.
Independent head-to-head outcomes data are not required for ANDA approval; therapeutic equivalence rests on bioequivalence and labeling sameness to the reference listed drug. Payers and GPOs will still negotiate separately on net price, 340B exposure, and outpatient buy-and-bill dynamics that shape real-world uptake in metastatic breast cancer clinics.
Analysts tracking Eisai oncology should separate Halaven U.S. erosion from other company franchises. A USD 43.7 million IQVIA base is modest versus large immuno-oncology brands, but it still matters for specialty injectable margin and for how quickly community oncology practices switch once a second source is stocked.
What remains unproven after the ANDA clearance?
The June 3, 2026 announcement did not disclose U.S. launch date, wholesale acquisition cost, or a contracted access share for the Natco–Lupin product.
It also did not claim superior efficacy versus Halaven. Buyers should treat this as a pricing and supply event until shipping and formulary data appear.
No ClinicalTrials.gov protocol was filed for comparative effectiveness of the generic versus Halaven, because ANDA policy does not require that study design. Claims about patient out-of-pocket savings percentages or hospital budget impact were absent from the release and should not be inferred.
Related NovaPharma coverage
- Breast Cancer Statistics Worldwide: What the Data Shows
- FDA approves Vyloy for HER2-negative gastric and GEJ cancer
- Eribulin mesylate drug profile
Frequently Asked Questions
What did the FDA approve for Eribulin Mesylate in June 2026?
On June 3, 2026, the FDA approved Natco’s ANDA for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, in partnership with Lupin. The product is bioequivalent to Eisai’s Halaven Injection.
Which patients can receive generic Eribulin Mesylate?
The label covers adults with metastatic breast cancer after at least two prior chemotherapy regimens for metastatic disease, and adults with unresectable or metastatic liposarcoma after a prior anthracycline-containing regimen.
How large was the Halaven U.S. market before generic entry?
Lupin and Natco cited IQVIA MAT April 2026 data putting U.S. sales for the Halaven reference product at about USD 43.7 million annually.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Eribulin Mesylate.
Unlock full calendar →Eisai Inc. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…